GEC-ESTRO APBI classification as a decision-making tool for the management of 2nd ipsilateral breast tumor event.
Details
Serval ID
serval:BIB_AE9E6C456F3B
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
GEC-ESTRO APBI classification as a decision-making tool for the management of 2nd ipsilateral breast tumor event.
Journal
Breast cancer research and treatment
ISSN
1573-7217 (Electronic)
ISSN-L
0167-6806
Publication state
Published
Issued date
07/2019
Peer-reviewed
Oui
Volume
176
Number
1
Pages
149-157
Language
english
Notes
Publication types: Journal Article
Publication Status: ppublish
Publication Status: ppublish
Abstract
Second ipsilateral breast tumor event (2ndIBTE) occurring after primary radio-surgical treatment can be treated by either salvage mastectomy or 2nd conservative treatment (2ndCT) including an accelerated partial breast re-irradiation (APBrI). We analyzed the impact of the GEC-ESTRO APBI classification (GAC) on the oncological outcome after APBrI.
Between 2000 and 2016, 159 patients (pts) underwent a 2ndCT. After lumpectomy, APBrI was performed using either low-dose (30-55 Gy reference isodose) or high-dose rate brachytherapy (28-34 Gy). Oncological outcome including 3rdIBTE, regional (RFS) or metastasis-free survival (MFS), specific (SS) and overall survival (OS) was analyzed according to GAC. Univariate (UVA) and multivariate analyses (MVA) were conducted to identify significant prognostic factors for 3rdIBTE.
With a median follow-up of 71 months (range 62-85 months), 60 pts (42%), 61 pts (42.7%) and 22 pts (15.4%) were classified as low-risk (LR), intermediate-risk (IR) and high-risk (HR), respectively. For the whole cohort, 6-year 3rdIBTE-free survival, RFS, MFS, SS and OS rates were 97.4, 96.4, 90.3, 92.9 and 91.2%, respectively. Six-year 3rdIBTE-free survival rates for LR, IR and HR were 100, 95.8 and 92.9%, respectively (p = 0.003), while no significant differences were found between the three GAC groups for RFS, MFS, SS. In UVA, lympho-vascular invasion (p = 0.009), positive margins (p = 0.0001) and GAC high-risk group (p = 0.001) were considered as significant prognostic factors for 3rdIBTE, while, in MVA, high-risk group (p = 0.009) was the only prognostic factor.
In case of 2ndIBTE, GAC could be used as a decision helping tool to discuss conservative or radical treatment options. Patient information remains crucial in order to accurately define the salvage therapy modalities.
Between 2000 and 2016, 159 patients (pts) underwent a 2ndCT. After lumpectomy, APBrI was performed using either low-dose (30-55 Gy reference isodose) or high-dose rate brachytherapy (28-34 Gy). Oncological outcome including 3rdIBTE, regional (RFS) or metastasis-free survival (MFS), specific (SS) and overall survival (OS) was analyzed according to GAC. Univariate (UVA) and multivariate analyses (MVA) were conducted to identify significant prognostic factors for 3rdIBTE.
With a median follow-up of 71 months (range 62-85 months), 60 pts (42%), 61 pts (42.7%) and 22 pts (15.4%) were classified as low-risk (LR), intermediate-risk (IR) and high-risk (HR), respectively. For the whole cohort, 6-year 3rdIBTE-free survival, RFS, MFS, SS and OS rates were 97.4, 96.4, 90.3, 92.9 and 91.2%, respectively. Six-year 3rdIBTE-free survival rates for LR, IR and HR were 100, 95.8 and 92.9%, respectively (p = 0.003), while no significant differences were found between the three GAC groups for RFS, MFS, SS. In UVA, lympho-vascular invasion (p = 0.009), positive margins (p = 0.0001) and GAC high-risk group (p = 0.001) were considered as significant prognostic factors for 3rdIBTE, while, in MVA, high-risk group (p = 0.009) was the only prognostic factor.
In case of 2ndIBTE, GAC could be used as a decision helping tool to discuss conservative or radical treatment options. Patient information remains crucial in order to accurately define the salvage therapy modalities.
Keywords
Adult, Aged, Aged, 80 and over, Brachytherapy/adverse effects, Breast Neoplasms/diagnosis, Breast Neoplasms/etiology, Breast Neoplasms/mortality, Breast Neoplasms/therapy, Clinical Decision-Making, Combined Modality Therapy/adverse effects, Combined Modality Therapy/methods, Decision Trees, Disease Management, Female, Follow-Up Studies, Humans, Middle Aged, Neoplasm Grading, Neoplasm Staging, Neoplasms, Second Primary/diagnosis, Neoplasms, Second Primary/etiology, Neoplasms, Second Primary/mortality, Neoplasms, Second Primary/therapy, Radiotherapy Dosage, Retrospective Studies, Brachytherapy, Breast cancer, Local recurrence, Partial breast irradiation, Salvage treatment, Treatment decision
Pubmed
Web of science
Publisher's website
Create date
23/08/2021 10:39
Last modification date
24/09/2024 11:08